Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX – Get Free Report)’s stock price traded down 1.1% on Friday . The company traded as low as $0.91 and last traded at $0.91. 795 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 17,504 shares. The stock had previously closed at $0.92.
Fresh Tracks Therapeutics Price Performance
The company has a market capitalization of $5.43 million, a price-to-earnings ratio of -0.65 and a beta of 0.39. The stock has a 50 day moving average price of $0.91 and a two-hundred day moving average price of $0.91.
Fresh Tracks Therapeutics (NASDAQ:FRTX – Get Free Report) last issued its earnings results on Friday, March 15th. The company reported ($0.20) earnings per share (EPS) for the quarter. Fresh Tracks Therapeutics had a negative return on equity of 60.83% and a negative net margin of 91.29%.
About Fresh Tracks Therapeutics
Fresh Tracks Therapeutics, Inc, a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops FRTX-02 (BBI-02), an oral DYRK1A inhibitor that is completed Phase 1 clinical trials for the treatment of autoimmune and inflammatory diseases; FRTX-10 (BBI-10), a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases; and FRTX-03, a topical DYRK1A inhibitor for the treatment of mild-to-moderate skin conditions, as well as next-generation kinase inhibitors.
See Also
- Five stocks we like better than Fresh Tracks Therapeutics
- What is the Shanghai Stock Exchange Composite Index?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is a buyback in stocks? A comprehensive guide for investors
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Bank Stocks – Best Bank Stocks to Invest In
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Fresh Tracks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresh Tracks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.